文献速递临床试验与 GCP

低剂量三联降压药与标准治疗方案对比:尼日利亚高血压治疗的随机临床试验

Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2024-01-01

在尼日利亚公立医院家庭医学诊所开展随机、平行组、开放标签、多中心试验,纳入300例未控制高血压的黑人非洲成人,比较低剂量三联药(替米沙坦/氨氯地平/吲达帕胺)加速滴定与标准治疗(起始氨氯地平5 mg)的疗效与安全性。6个月时三联药组家庭收缩压降幅更大(组间校正差值-5.8 mmHg),家庭血压达标率更高(62% vs 28%),无因不良事件停药。

要点

  • 低剂量三联药方案6个月家庭收缩压降幅较标准治疗多5.8 mmHg(95%CI -8.0至-3.6)。
  • 家庭血压达标率(<130/80 mmHg)三联药组62% vs 标准治疗组28%。
  • 两组均无参与者因不良事件停止试验治疗。

核心结论

  • 在未控制高血压的黑人非洲成人中,低剂量三联药方案较标准治疗方案实现更好的血压降低和达标,且耐受性良好。

研究设计与样本

  • 随机、平行组、开放标签、多中心试验,在尼日利亚公立医院家庭医学诊所开展,纳入300例未治疗或单药治疗未控制高血压(≥140/90 mmHg)的黑人非洲成人。

主要发现

  • 6个月时家庭平均收缩压三联药组降低31 mmHg(95%CI 28至33),标准治疗组降低26 mmHg(95%CI 22至28),校正差值-5.8 mmHg(95%CI -8.0至-3.6;P<.001)。
  • 6个月时诊所血压达标(<140/90 mmHg)三联药组82% vs 标准治疗组72%(风险差10%,95%CI -2%至20%)。
  • 6个月时家庭血压达标(<130/80 mmHg)三联药组62% vs 标准治疗组28%(风险差33%,95%CI 22%至44%)。
  • 无参与者因不良事件停止试验治疗。

关键数值与推荐

  • 三联药方案为替米沙坦、氨氯地平、吲达帕胺组合,三阶段剂量分别为10/1.25/0.625 mg、20/2.5/1.25 mg和40/5/2.5 mg,加速上调滴定。
  • 标准治疗方案为尼日利亚高血压治疗方案,起始氨氯地平5 mg。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: With the high burden of hypertension in sub-Saharan Africa, there is a need for effective, safe and scalable treatment strategies. OBJECTIVE: To compare, among Black African adults, the effectiveness and safety of a novel low-dose triple-pill protocol compared with a standard-care protocol for blood pressure lowering. DESIGN AND SETTING: Randomized, parallel-group, open-label, multicenter trial conducted in public hospital-based family medicine clinics in Nigeria. PARTICIPANTS: Black African adults with uncontrolled hypertension (≥140/90 mm Hg) who were untreated or receiving a single blood pressure-lowering drug. INTERVENTIONS: Participants were randomly allocated to low-dose triple-pill or standard-care protocols. The triple-pill protocol involved a novel combination of telmisartan, amlodipine, and indapamide in triple one-quarter, one-half, and standard doses (ie, 10/1.25/0.625 mg, 20/2.5/1.25 mg, and 40/5/2.5 mg), with accelerated up-titration. The standard-care protocol was the Nigeria hypertension treatment protocol starting with amlodipine (5 mg). MAIN OUTCOMES AND MEASURES: The primary effectiveness outcome was the reduction in home mean systolic blood pressure, and the primary safety outcome was discontinuation of trial treatment due to adverse events, both from randomization to month 6. RESULTS: The first participant was randomized on July 19, 2022, and the last follow-up visit was on July 18, 2024. Among 300 randomized participants (54% female; mean age, 52 years; baseline mean home blood pressure, 151/97 mm Hg; and clinic blood pressure, 156/97 mm Hg), 273 (91%) completed the trial. At month 6, mean home systolic blood pressure was on average 31 mm Hg (95% CI, 28 to 33 mm Hg) lower in the triple-pill protocol group and 26 mm Hg (95% CI, 22 to 28 mm Hg) lower in the standard-care protocol group (adjusted difference, -5.8 mm Hg [95% CI, -8.0 to -3.6]; P < .001]). At month 6, clinic blood pressure control (<140/90 mm Hg) was 82% vs 72% (risk difference, 10% [95% CI, -2% to 20%]) and home blood pressure control (<130/80 mm Hg) was 62% vs 28% (risk difference, 33% [95% CI, 22% to 44%]) in the triple-pill compared with the standard-care protocol group; these were 2 of 21 prespecified secondary effectiveness end points. No participants discontinued trial treatment due to adverse events. CONCLUSIONS AND RELEVANCE: Among Black African adults with uncontrolled hypertension, a low-dose triple-pill protocol achieved better blood pressure lowering and control with good tolerability compared with the standard-care protocol. TRIAL REGISTRATION: Pan African Clinical Trials Registry Identifier: PACTR202107579572114.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Ojji DB, Salam A, Sani MU, et al. Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial. JAMA. 2024. PMID: 39215620. doi:10.1001/jama.2024.18080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。